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Abstract—With the aid of Atomic Force Microscopy (AFM) and 
Surface Plasmon Resonance (SPR), the interaction of 
chlorpromazine (CPZ) with phosphatidylcholine bilayer 
membranes was investigated. The interaction of CPZ had 
inherent effects on the transition temperature (TM), and hence, 
fluidity of DMPC phospholipid membranes. It was discovered 
that CPZ intercalates within the membrane bilayers to form a 
drug/phospholipid complex. 
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I. INTRODUCTION
Previous approaches in drug design have typically focused 
on interactions of ligand molecules with proteins, such that the 
lipid environment has been considered to play a more passive 
role. However, it is now apparent that drug substrates may 
interact with membrane constituents, particularly via charged 
head groups [1]. It is recognised that such interactions can 
influence drug partitioning, orientation and conformation 
within the membrane. Although there are intrinsic effects on 
drug substrates, complimentary effects on membrane fluidity, 
curvature or phase separation may also potentially occur. 
Ultimately, these alterations can induce changes in the 
performance of cells, with the ability to affect the function of 
transmembrane receptor proteins and/or proteins responsible 
for signal transduction [1]. In view of the current need for 
further understanding of drug-membrane interactions, the aim 
of this research is to investigate membrane interactions using 
SPR and AFM. 
In order to promote an understanding of membrane related 
processes, supported phospholipid bilayers (SPBs) can be used 
as simple model systems for biological membranes [2, 3]. In 
this paper we will present the formation and characterisation of 
SPBs on mica, in addition to lipid membrane vesicles anchored 
to lipophilic groups covalently attached to Au substrates. The 
integrity of the bilayer structure is maintained whereby the 
interaction of CPZ has also been demonstrated. 
II. EXPERIMENTAL
Multilamellar vesicles (MLVs) were prepared by first 
dissolving aliquots of lipid (either 1,2-dioleoyl-sn-glycero-3-
phosphocholine (DOPC), 1,2-dimyristoyl-sn-glycero-3-
phosphocholine (DMPC) or 1,2-distearoyl-sn-glycero-3-
phosphocholine (DSPC)), in chloroform/methanol (3:1 v:v), 
followed by evaporation of the solvent under nitrogen. Lipid 
samples were further dried under vacuum for 3hr prior to being 
suspended in 10mM Hepes buffer containing 150mM NaCl 
(pH 5.5). The final concentration of lipids was 1mM. Samples 
were left to hydrate overnight, followed by sonication for 1hr. 
During sonication, periodic vortex mixing was carried out prior 
to their extrusion (Avanti Mini-Extruder, Avanti Polar Lipids, 
Birmingham, AL) 30 times through a polycarbonate membrane 
filter of defined pore diameter, typically 100 nm. Extrusion 
was performed at temperatures higher than the transition 
temperature (TM) of the component phospholipids, as gel-state 
lipids are difficult to extrude at lower temperatures. Resultant 
small unilamellar vesicles (SUVs) yielded a homogenous size 
distribution and were used for all further experiments. 
The visualization of SPBs were performed using a 
commercial AFM (Nanoscope IV, Digital Instruments, Santa 
Barbara, CA). All images were obtained by means of in situ
tapping mode using triangular Si3N4 cantilevers (Digital 
Instruments) which had a spring constant of 0.15 N/m. 
Formation of SPBs was achieved by depositing 100PL of 
100nm SUV solution (10mM Hepes 150mM NaCl 2mM 
CaCl2, pH 5.5 or 7.4) to a freshly cleaved mica surface. 
Prepared surfaces were then incubated at temperatures greater 
than their gel-fluid phase TM for 3hrs to promote SPB 
formation. Prior to imaging, bilayer surfaces were washed 5 
times with an appropriate buffer. 
SPR studies were performed at 25°C using a Biacore 2000 
(Biacore AB, Uppsala Sweden) biosensor equipped with an L1 
sensor chip (Biacore AB, Uppsala Sweden). Fig 1. depicts a 
typical binding cycle of SUVs on an L1 sensor chip. Prior to 
each experiment sensor chips were preconditioned with 100PL
of non-ionic detergent (40mM Octyl ȕ-D-glucopyranoside). 
Membrane vesicles were subsequently attached to lipophilic 
groups of the L1 sensor chip at a flow rate of 2PL/min in a 
running buffer of 10mM Hepes, 150mM NaCl, 1% DMSO, pH 
5.5. Resulting phospholipid bilayers were washed with 20mM 
NaOH prior to drug analysis. Drug injections were performed 
at a flow rate of 100PL/min and were preformed in triplicate. 
Regeneration of the L1 sensor chip was accomplished by 
performing a second injection of non-ionic detergent. To avoid 
carryover between experiments, a new lipid membrane surface 
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was regenerated for each drug-binding cycle. All data were 
double-referenced to account for bulk refractive index changes 
and systematic effects throughout the course of an experiment. 
Figure 1. Sensorgram illustrating preconditioning, vesicle capture, NaOH 
wash, drug binding and regeneration. DOPC vesicles and CPZ (500PM) were 
utilised for the current sensorgram, representative of vesicle capture and drug 
binding respectively. 
III. RESULTS & DISCUSSION
Upon exposing a SUV suspension to a ‘muscovite’ mica 
surface, vesicles adhere to the surface, rupture, and spread to 
form a planar phospholipid bilayer [2]. As the zwitterionic lipid 
phosphatidylcholine is the most abundant lipid found in 
biomembranes, investigations utilised phospholipid vesicles 
that contained DMPC. As DMPC has a TM of 23oC, the gel and 
fluid phases were distinguished by topography AFM images 
(Fig. 2a) at ambient room temperature. The immiscibility 
between the gel and fluid phase exhibited a height difference of 
~ 0.57nm which is in close agreement with previous studies [4, 
5]. Fig. 2b illustrates a typical topographical image of DMPC 
where no phase separation is observed. Numerous elongated 
defects were present, due to ‘cracks’ in the planar bilayer. 
Cross-section analysis (Fig. 2c, d) of defects located at 
different locations demonstrated a height difference of ~4.1nm 
confirming the observed bilayer was in its gel phase [4, 5].
Figure 2. AFM images of DMPC on mica. a) Surface plot image exhibiting 
phase separation between fluid and gel domains. b) Height image of gel phase 
bilayer. c) Section analysis of d) membrane defects.
Membrane surfaces of DOPC, DMPC and DSPC were 
prepared. To each membrane surface the interaction of CPZ 
was analysed. A concentration range between 15.625 to 
1500PM was investigated (Fig. 3b). In a plot of equilibrium 
drug-binding response (Req) versus concentration (C), two 
processes were evident. Based on data for concentrations 
betweeen 15.625 and 500PM, fitted single-site equilibrium-
binding isotherms (1) were extrapolated to 1500PM. When the 
experimentally determined single-site equilibrium-binding 
isotherm between 750 and 1500PM was overlaid (Fig. 3b), it 
was evident a second process was taking place for each 
phospholipid bilayer. 
 Req = Rmax/((KD/C) + 1)  
a) b)
Figure 3. Concentration dependent (a) sensorgrams of CPZ interacting with 
DOPC membrane surfaces and (b) response plots for CPZ binding to DOPC 
(ź), DMPC (Ŷ) and DSPC (Ɣ) membrane surfaces for CAD concentrations 
between 15.625 and 1500PM. Points are experimentally determined values 
while the continuous curves from 0-1500PM are from model fitting. 
The first process, which was observed for concentrations 
between 15.625 and 500PM, exhibits saturable binding. This 
process, also reported by others, presumably arises from 
electrostatic and hydrophobic interactions where the negatively 
charged phosphate headgroup interacts with the positively 
charged amine group of the drug while the lipophilic groups 
align with the hydrophobic carbon chains of the bilayer [6-8]. 
Recent studies have also yielded results consistent with the 
electrostatic interactions being of paramount importance [9, 
10]. The second process may be considered a high capacity, 
low affinity process. It has only been referred to previously in 
relation to SPR sensorgrams where a heterogeneous interaction 
was established [11, 12]. Previous studies utilising 1, 2-
dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) 
phospholipid vesicles and lamellar bodies has also reported two 
binding affinities for CPZ over the concentration range 
employed in the current study [13, 14]. 
b)a) 
A comparison between the alkyl chain lengths and 
molecular structure for three phospholipid molecules (DOPC, 
DSPC and DSPC) on drug binding responses was investigated. 
It was demonstrated that each drug exhibited a much larger 
interaction to bilayers comprising DOPC. DOPC phospholipid 
molecules possess a TM of -20oC and therefore exhibit greater 
membrane fluidity than bilayer surfaces comprised of either 
DMPC (TM of 23oC) or DSPC (TM of 55oC). As experiments 
were performed at 25oC, the trend observed suggests binding is 
a function of membrane fluidity. CPZ exhibited greater binding 
to DOPC phospholipid vesicles which were in their liquid 
crystalline state, followed by DMPC surfaces that displayed a 
c) d)
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gel-liquid crystalline phase [15] and, lastly, DSPC vesicles that 
were in their gel phase. Membranes that exhibit greater fluidity 
provide a more flexible structure for drug binding, and hence 
the ability of each drug molecule to partition into the bilayer is 
a more readily achievable process. 
With respect to Fig. 3b, the uptake of CPZ to DMPC 
phospholipid bilayers increased markedly at concentrations 
greater than 750PM. In particular, the increase in response was 
greater than those observed for experiments utilising DOPC 
within the same concentration range. This is related to a 
lowering in TM of the phospholipid which is an effect that has 
been associated with the partitioning of drugs into phospholipid 
hydrocarbon chains [1, 16-18]. A lowering in the TM of DMPC 
would have potentially promoted the formation of a more fluid 
phase bilayer. As drug injections were performed at 100Pl/min
for 2 minutes, it is difficult to comment on the magnitude of 
this effect during this time period. However, as there was a 
significant increase in response for concentrations between 750 
and 1500PM, this may be indicative of an increase in 
membrane fluidity. An increase in membrane fluidity of 
DMPC vesicles through the electrostatic and hydrophobic 
interactions of CPZ may have promoted a more flexible 
process for drug binding and, as a result, contributed to the 
observed increase in SPR response, consistent with our results 
showing greater binding in more fluid membranes. In contrast, 
effects of CPZ on the TM of DOPC surfaces are not expected to 
change the fluidity as DOPC has a TM of -20oC, and it is 
therefore evident that these bilayers were in a complete liquid 
phase at 25oC.
With the aid of AFM, the effect of CPZ on the molecular 
organisation of DMPC SPBs has been investigated. 
Reinforcing previous SPR results, CPZ affected membrane 
fluidity, whereby time-lapse AFM images recorded the 
disappearance of DMPC gel domains. To confirm the change 
in morphology of DMPC, SPBs were initially scanned for 45 
minutes prior to drug injection. As consecutive scanning of the 
AFM tip can potentially alter image contrast or create artificial 
features, it was important to assess the stability of the 
phospholipid bilayer. As previously noted, DMPC has a TM of 
23oC and it was important to determine any phase changes due 
to fluctuations in ambient room temperature. As experiments 
were constantly performed at ~23oC, the immiscibility 
between gel and fluid phases was observed, this also being 
consistent with previous reports (Fig 4) [4, 5, 15]. Over the 
duration of 45 minutes, continuous scanning of a 2Pm area did 
not cause any significant changes on surface morphology. 
               
Figure 4. AFM images of DMPC on mica. Section analysis of fluid and gel 
domains, representative of 0.55nm.  
After the injection of 125PM CPZ, time-lapsed AFM 
images at the same location were recorded. A series of 
topographic images were recorded at 10, 27, 35, 45, 61, and 70 
minutes after CPZ injection (Fig 5). The moment the cantilever 
tip began to scan the surface; it was evident that the 
morphology of the bilayer was strongly affected. Over the 
duration of imaging there was a progressive decrease in the 
size of gel domains until they had completely disappeared. 
Interestingly, a defect in the bilayer was also observed 
throughout the course of imaging.  
 10 mins    27 mins    35 mins 
 45 mins  61 mins    70 mins 
Figure 4. AFM height images (2.0 x 2.0 Pm; z-scale: 5nm) of a DMPC 
bilayer recorded in a solution of 125PM CPZ at increasing incubation times. 
Previously referred to as the ‘first process’ in relation to 
SPR data, we believe the observed affect was attributable to the 
electrostatic and hydrophobic interactions of CPZ in the lipid 
bilayer [19]. As a result, the drug potentially disrupts the 
interactions between the lipid polar headgroups and interfacial 
domains, affecting the TM of the lipid bilayer as the 
phospholipids became further disordered and possess more 
motional freedom [19, 20]. In comparison to SPR data, the 
effect of CPZ on the TM of DMPC was observed at a much 
lower concentration, however, it also important to once again 
establish that the interaction observed using SPR was during a 
much shorter time period, typically 2 minutes. 
A 5Pm topographical image was recorded at the end of the 
time-dependent experiment. It was revealed that other locations 
on the surface also demonstrated a complete liquid crystalline 
phase (Fig 5a). An increased number of defects in the bilayer 
were also observed. Cross-section analysis of these defects 
(Fig. 5b) revealed they were equivalent to the upper monolayer 
of a liquid crystalline bilayer (~1.8nm) [4]. 
0.55nm
b)
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Figure 5. (a) AFM height image (5.0 x 5.0 Pm; z-scale: 5nm) of a DMPC 
bilayer recorded in solution of 125PM CPZ and (b) section analysis of defects. 
These bilayer defects are associated with a drug induced 
disruption. Electron cryo-microscopy studies have also 
proposed that a drug from the same family as CPZ disrupts the 
bilayer by perturbation of the local organisation of 
phospholipids [21]. In the current study, it also postulated that 
the second process represents intercalation of each drug, 
forming a drug/phospholipid complex [22, 23] as drugs did not 
dissociate completely from the membrane as evidenced by the 
residual response in SPR following exposure to the drug. It has 
been proposed that formation of drug/phospholipid complexes 
mimics phospholipidosis [14, 19, 23], a type of lipid storage 
disorder [24] which could give rise to the observed defects. 
SPR and AFM have proven to be effective tools for the 
analysis of drug-phospholipid bilayer interactions. Extending 
previous research, it has been shown that CPZ binding involves 
two discrete processes. An effect of membrane fluidity on drug 
binding was also demonstrated, such that phospholipid bilayers 
that exhibit a complete liquid phase bilayer permit greater drug 
partitioning, and hence greater drug uptake. The effect of CPZ 
on the TM of component phospholipids was also observed, 
indicative of the complementary effects associated with 
membrane partitioning of drugs. These experiments show that 
the methods used in the current study are potentially useful for 
the evaluation of drug-membrane binding interactions of new 
drug candidates and for providing insights into the processes 
that contribute to drug-membrane binding. 
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